|
|
|
Insider
Information: |
Katkin Keith |
Relationship: |
Director |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
1,258,490 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$4,827,703 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
1,258,490 |
|
|
Total
Value |
$4,827,703 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Avanir Pharmaceuticals |
AVNR |
President and CEO, Dir... |
2014-12-17 |
914,249 |
2006-05-25 |
0 |
Premium* |
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
Director |
2017-05-10 |
12,119 |
|
0 |
Premium* |
|
Urovant Sciences Ltd. |
UROV |
PEO;CEO/Urovant Scienc... |
2020-02-19 |
199,680 |
2019-12-09 |
0 |
Premium* |
|
Syndax Pharmaceuticals Inc |
SNDX |
|
2024-02-07 |
65,000 |
2021-02-03 |
0 |
Premium* |
|
Rigel Pharmaceuticals Inc |
RIGL |
Director |
2021-05-19 |
25,000 |
2021-05-19 |
0 |
Premium* |
|
Emergent Biosolutions Inc. |
EBS |
Director |
2023-05-25 |
42,442 |
2022-04-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
76 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
AVNR |
Avanir Pharmaceuticals |
Sr. V.P. of Sales & Marketing |
|
2006-05-25 |
4 |
B |
$8.98 |
$22,484 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
AVNR |
Avanir Pharmaceuticals |
Sr. V.P. of Sales & Marketing |
|
2006-12-13 |
4 |
A |
$0.00 |
$0 |
D/D |
57,600 |
60,100 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2007-03-21 |
4 |
A |
$0.00 |
$0 |
D/D |
526,316 |
586,416 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2007-12-13 |
4 |
D |
$1.66 |
$8,546 |
D/D |
(5,148) |
581,268 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2008-03-13 |
4 |
D |
$1.10 |
$1,693 |
D/D |
(1,539) |
579,729 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2008-06-13 |
4 |
D |
$1.11 |
$1,429 |
D/D |
(1,287) |
578,442 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2009-02-24 |
4 |
B |
$0.43 |
$6,591 |
D/D |
15,000 |
593,442 |
2.81 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2009-06-13 |
4 |
D |
$1.31 |
$1,686 |
D/D |
(1,287) |
592,155 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2009-07-15 |
4 |
D |
$2.13 |
$100,197 |
D/D |
(47,041) |
545,114 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2009-09-13 |
4 |
D |
$2.21 |
$2,844 |
D/D |
(1,287) |
543,827 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2009-12-13 |
4 |
D |
$1.82 |
$2,402 |
D/D |
(1,320) |
542,507 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2009-12-15 |
4 |
S |
$1.81 |
$68,025 |
D/D |
(37,335) |
505,172 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-01-04 |
4 |
S |
$1.88 |
$38,005 |
D/D |
(20,000) |
433,026 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-01-04 |
4 |
D |
$1.97 |
$102,728 |
D/D |
(52,146) |
453,026 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-01-04 |
4/A |
S |
$1.88 |
$38,005 |
D/D |
(20,000) |
433,615 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-01-04 |
4/A |
D |
$1.97 |
$101,567 |
D/D |
(51,557) |
453,615 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-01-05 |
4/A |
S |
$1.93 |
$29,276 |
D/D |
(15,025) |
418,590 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-01-05 |
4 |
S |
$1.93 |
$29,276 |
D/D |
(15,025) |
418,001 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-03-13 |
4 |
D |
$2.13 |
$2,805 |
D/D |
(1,317) |
417,273 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-03-29 |
4 |
AS |
$2.60 |
$78,000 |
D/D |
(30,000) |
387,273 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-04-08 |
4 |
AS |
$3.01 |
$30,100 |
D/D |
(10,000) |
377,273 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-04-30 |
4 |
AS |
$3.31 |
$132,372 |
D/D |
(40,000) |
337,273 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-05-03 |
4 |
AS |
$3.06 |
$201,376 |
D/D |
(65,906) |
271,367 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-06-13 |
4 |
D |
$2.71 |
$3,577 |
D/D |
(1,320) |
270,047 |
0 |
- |
|
AVNR |
Avanir Pharmaceuticals |
President and CEO |
|
2010-09-13 |
4 |
D |
$2.70 |
$3,567 |
D/D |
(1,321) |
165,852 |
0 |
- |
|
76 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|